Cureus . Current Use of Baricitinib in COVID-19 Treatment and Its Future: An Updated Literature Review

[tetano]

Cureus


. 2022 Sep 1;14(9):e28680.
doi: 10.7759/cureus.28680. eCollection 2022 Sep.
Current Use of Baricitinib in COVID-19 Treatment and Its Future: An Updated Literature Review


Derma Dupuis ¹ , Kasinda Fritz ¹ , Emeka Ike ¹ , Oyinkansola Arogundade ¹ , Enoch O Adewara ² , Esther O Monday ² , Bolaji O Ayinde ²



Affiliations

• PMID: 36199657
• PMCID: PMC9526681
• DOI: 10.7759/cureus.28680

Abstract

The levels of infectivity and mortality that ensued due to the coronavirus disease 2019 (COVID-19) pandemic caused an apparent global outcry. The health system, burdened by increasing deaths and hospitalizations, sought more effective treatment. This necessitated scientists and researchers to utilize existing drugs such as baricitinib, which has proved itself as anti-inflammatory and immunomodulatory. A qualitative systematic review was conducted using databases such as Google Scholar, Science Direct, PubMed, and BioMed Central to locate relevant articles published from 2019 onward on the effectiveness of baricitinib. After evaluation of the full-text articles, 16 were selected for review. Overall, baricitinib was seen as beneficial in decreasing respiratory failure and the use of mechanical ventilation, also preventing deterioration of COVID-19 symptoms. When used as a single agent or combined with other drugs, baricitinib improves the peripheral capillary oxygen saturation (SpO2)/fraction of inspired oxygen (FiO2) ratio. The drug does not introduce any major side effects, but a mild increase in liver enzymes has been observed. Baricitinib proves to be a safe and effective treatment for COVID-19. Administered as monotherapy or in conjunction with other drugs, baricitinib provides tremendous clinical benefit to infected patients and shows good potential in terms of efficacy for future COVID-19 regimens.

Keywords: baricitinib; coronavirus; covid-19; jak-stat; janus kinase inhibitors; sars-cov-2.